Synergistic combination of immunologic inhibitors for the treatment of cancer
作者： Thomas F. Gajewski , Stefani Spranger , Michael Leung
DOI:
关键词:
摘要: In some embodiments, the methods involve use of a combination at least two following: an inhibitor indoleamine-2,3-dioxygenase (IDO), PD-L1/PD-1 pathway, CTLA-4, CD25, or IL-7. The inventors particularly observed major synergistic effect combining anti-CTLA-4 with either IDO inhibitor, anti-PD-L1 mAb, CD-25 depletion. Such combinations have been found to demonstrate in treating cancer and tumors, for example by reducing tumor size, increasing percentage antigen-specific T cells, cell function.
lens.org 参考文章(42)
Satoshi Tanda, Norihiko Nishiguchi, Ryuji Morita, Atsushi Taniguchi, Taisuke Ogoshi, Kazuhiko Oka, Light vortex generator, microobject operating unit, astronomical probing equipment, and polarization vortex transformation element ,(2006)
Vadivel Ganapathy, Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase ,(2011)
Bruce R. Blazar, Madhav D. Sharma, Andrew L. Mellor, David H. Munn, Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells ,(2008)
Douglas Charles Hanson, Mark Joseph Neveu, Jeffrey Herbert Hanke, Steven Christopher Gilman, Jose Ramon Corvalan, C. Geoffrey Davis, Eileen Elliott Mueller, Methods for expressing and recovering human monoclonal antibodies to CTLA-4 ,(2003)
Andrew Mellor, David Munn, Antigen-Presenting Cell Populations And Their Use As Reagents For Enhancing Or Reducing Immune Tolerance ,(2002)
Kutlu G Elpek, Chantale Lacelle, Narendra P Singh, Esma S Yolcu, Haval Shirwan, None, CD4+CD25+ T Regulatory Cells Dominate Multiple Immune Evasion Mechanisms in Early but Not Late Phases of Tumor Development in a B Cell Lymphoma Model Journal of Immunology. ,vol. 178, pp. 6840- 6848 ,(2007) , 10.4049/JIMMUNOL.178.11.6840
Walter Däubener, Colin R. MacKenzie, Ifn-γ Activated Indoleamine 2,3-Dioxygenase Activity in Human Cells is an Antiparasitic and an Antibacterial Effector Mechanism Advances in Experimental Medicine and Biology. ,vol. 467, pp. 517- 524 ,(1999) , 10.1007/978-1-4615-4709-9_64
Nils Lonberg, Edward L. Halk, Alan J. Korman, Yashwant M. Deo, Tibor P. Keler, Human CTLA-4 antibodies ,(2000)
George C. Prendergast, Alexander J. Muller, William Malachowski, James B. Duhadaway, Novel ido inhibitors and methods of use ,(2004)
Peter S. Linsley, Nitin K. Damle, Jeffrey A. Ledbetter, William Brady, Methods for treating cancer and infectious disease by blocking CTLA4-B7 interactions ,(2003)